BIRC2 and glioblastoma: Given that BIRC2 and BIRC3 were the downstream targets of Xevinapant, we were interested in further investigating the relationship between BIRC2/BIRC3 and the TME in order to gain insights as to how Xevinapant could be leveraged to favorably modulate the GBM TME.